Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine (WOKVAC) Encoding Epitopes Derived From Three Breast Cancer Antigens (IGFBP-2, HER2, and IGF-1R) in Patients With Breast Cancer

NCT02780401 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT02780401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02780401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine (WOKVAC) Encoding Epitopes Derived From Three Breast Cancer Antigens (IGFBP-2, HER2, and IGF-1R) in Patients With Breast Cancer
Lead sponsor
University of Washington
Phase
Phase 1
Overall status
Completed
Start date
September 2, 2016
Completion date
October 8, 2022
Enrollment
32 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

her2/neu negative, no evidence of disease, one or more positive axillary nodes, stage ib breast cancer, stage ii breast cancer, stage iia breast cancer, stage iib breast cancer, stage iii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer